ASCO 2016 | Trial of durvalumab for bladder cancer

Thomas Powles, MD, PhD from Barts Cancer Institute, London, UK discusses key points of a new Phase III clinical trial looking at moving immune single agent and immune combination therapy into the frontline setting in bladder cancer (NCT02516241). The trial has three arms: chemotherapy vs. single agent durvalumab vs. a combination of durvalumab and tremelimumab. The hope is that chemotherapy can be replaced. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.